Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

Program in Cancer Genetics, McGill University, Montréal, Québec, Canada.
BMC Cancer (Impact Factor: 3.32). 02/2007; 7(1):134. DOI: 10.1186/1471-2407-7-134
Source: PubMed

ABSTRACT Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP).
There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors (beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival increased with time, becoming more pronounced at 10 years than at 3 years.
Our findings suggests that CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term, an observation that may have important therapeutic implications as drugs that target the EGFR are currently being evaluated in breast cancer.


Available from: Jean-Sébastien Brunet, Jun 13, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical decisions regarding the suitability of adjuvant systemic therapy for individual patients with breast cancer depends on comprehensive assessment of the underlying biology of each patient's tumor. The previous clinical-pathologic paradigm for treatment, which had been used for decades, now has been augmented by significant advances in molecular analysis of breast tumor tissue samples. Molecular testing has the potential to understand better both tumor biology and clinical behavior, which enables more appropriate therapy choices to be made. We review the rapid evolution in profiling breast cancer tissues, and discuss the current evidence for clinical use of this information and how the emerging molecular paradigm can be integrated into the clinical-pathologic context as we progress toward "precision" therapy for patients with breast cancer and other solid tumors.
    Biotechnic and Histochemistry 12/2014; 90(2):1-12. DOI:10.3109/10520295.2014.978893 · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Numerous studies have paid attention to the role of the triple-negative marker in the prognosis of breast cancer, but very few studies have combined mammographic phenotypes with the triple-negative marker to assess their relevance to the long-term prognosis of breast cancer. The current study aims to assess the respective contributions of both mammographic tumour appearance and the triple-negative marker, and their possible interactions, on the long-term survival of breast cancer, taking into account the prognostic factors already established.
    Cancer Epidemiology 02/2015; 39(2). DOI:10.1016/j.canep.2015.01.013 · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Molecular classification of breast carcinoma offers much better characterization of breast tumours and identifies the basal subtype, which has been studied extensively because of its unique prognostic implications. Objective: To identify basal breast carcinoma among triple-negative tumours [oestrogen receptor (ER), progesterone receptor (PR) and Her2neu negative] by immunohistochemical expression of cytokeratin 5/6 (CK5/6) and/or epidermal growth factor receptor (EGFR) and to study their morphological characteristics. Materials and methods: The study included 34 cases of breast ductal carcinoma with a triple-negative immunophenotype (ER, PR and HER2neu negative) that were received at the pathology departments of Ain Shams University Hospitals. Clinical data were retrieved from the archival files and all cases were subjected to a histopathological evaluation as well as immunohistochemical staining for CK5/6 and EGFR. Cases with focal clear cell change (six cases) as well as spindle cell change (three cases) were also stained for S100. Results: Among the 34 triple-negative cases, 20 cases (58.8%) were considered of the basal subtype as they expressed CK5/6 (52.9%) and/or EGFR (52.9%). Combined positivity for both markers was found in 80% of the positive cases. The main histological subtype in the study was invasive duct carcinoma not otherwise specified, with fewer percentages of medullary, mucinous and squamous subtypes. Negative lymph node status was predominant in the entire group and particularly in the basal group. Ductal carcinoma in situ was found in 35.3% of all cases and in 40% of the cases in the basal group. The salient morphological characteristics of the entire triple-negative group as well as the basal group included pushing tumour border, geographical tumour necrosis, central scar, prominent lymphoplasmacytic infiltrate, high tumour grade and sheet-like and ribbon growth patterns. Focal clear cell change as well as focal spindle cell change were also found in 30 and 15%, respectively, of the cases in the basal group. Conclusion: Triple-negative and basal breast carcinoma had some common morphological criteria that were more often encountered in the basal subtype; however, they are not diagnostic for the basal phenotype, and therefore, immunohistochemical staining for CK5/6 and/or EGFR is useful for the identification of such tumours.
    01/2012; 32(1):6-13. DOI:10.1097/01.XEJ.0000417553.95276.37